Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
This study has been completed.
Study NCT00751205 Information provided by Bayer
First Received on September 10, 2008. Last Updated on October 25, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostate Cancer
Ovarian Cancer
Additional conditions recognized in this trial
Ovarian Neoplasms
Peripheral Nervous System Diseases
Prostatic Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Diseases, Male
Genital Neoplasms, Female
Genital Neoplasms, Male
Gonadal Disorders
Neoplasms
Neoplasms by Site
Nervous System Diseases
Neuromuscular Diseases
Ovarian Diseases
Prostatic Diseases
Urogenital Neoplasms
Additional drug interventions recognized in this trial
Acetylcarnitine
Carnitine
Epothilones
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Prednisone
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antiemetics
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Growth Substances
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Micronutrients
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Nootropic Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Tubulin Modulators
Vitamin B Complex
Vitamins
Sponsors listed in this trial
Bayer
Back to top of Main Content
